Literature DB >> 8169194

Clozapine for schizophrenia.

Y Levkovitch, N Kaysar, Y Kronnenberg, H Hagai, B Gaoni.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8169194     DOI： 10.1097/00004583-199403000-00026

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN： 0890-8567            Impact factor:   8.829


× No keyword cloud information.
  6 in total

Review 1.  Atypical neuroleptics in child and adolescent psychiatry.

Authors:  H Remschmidt; K Hennighausen; H W Clement; P Heiser; E Schulz
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 2.  Tolerability profile of atypical antipsychotics in children and adolescents.

Authors:  K A Stigler; M N Potenza; C J McDougle
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.

Authors:  Paz Toren; Sharon Ratner; Nathaniel Laor; Abraham Weizman
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 4.  Management of schizophrenia in children and adolescents. The role of clozapine.

Authors:  H Remschmidt; C Fleischhaker; K Hennighausen; E Schulz
Journal:  Paediatr Drugs       Date:  2000 Jul-Aug       Impact factor: 3.930

Review 5.  Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia.

Authors:  Sanjiv Kumra; Joel V Oberstar; Linmarie Sikich; Robert L Findling; Jon M McClellan; Sophia Vinogradov; S Charles Schulz
Journal:  Schizophr Bull       Date:  2007-10-08       Impact factor: 9.306

Review 6.  Antipsychotics in children and adolescents with schizophrenia: a systematic review and meta-analysis.

Authors:  Siddharth Sarkar; Sandeep Grover
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.